Nuvalent (NUVL) Other Working Capital Changes (2020 - 2026)
Nuvalent's (NUVL) quarterly Other Working Capital Changes came in at $3.0 million in Q1 2026, down 66.94% YoY from $9.2 million in Q1 2025, and down 54.32% on a QoQ basis from $6.6 million in Q4 2025.
Analysis
Nuvalent (NUVL) Other Working Capital Changes (2020 - 2026) Analysis & Trends
Nuvalent (NUVL) has 7 years of Other Working Capital Changes data on file, last reported at $3.0 million in Q1 2026.
- Quarterly Other Working Capital Changes fell 66.94% year-over-year to $3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $195000.0 (down 98.57% YoY) and the FY2025 annual result came in at $6.3 million, down 16.14% from the prior year.
- Other Working Capital Changes retreated to $3.0 million in Q1 2026, from $6.6 million in the prior quarter.
- In the past five years, Other Working Capital Changes ranged from a high of $9.2 million in Q1 2025 to a low of -$11.3 million in Q3 2025.
- A 5-year average of $1.1 million and a median of $1.0 million in 2022 frame the typical range for Other Working Capital Changes.
- Annual changes were most pronounced in 2022 — Other Working Capital Changes plunged 3000.0% — and 2024, when it surged 3988.24%.
- Tracing NUVL's Other Working Capital Changes over 5 years: stood at $374000.0 in 2022, then slumped by 81.82% to $68000.0 in 2023, then surged by 3988.24% to $2.8 million in 2024, then surged by 139.06% to $6.6 million in 2025, then tumbled by 54.32% to $3.0 million in 2026.
- The last three Other Working Capital Changes figures came in at $3.0 million (Q1 2026), $6.6 million (Q4 2025), and -$11.3 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Nuvalent | 9.75 Bn | 9.75 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 3,000.00 |
| Mar 31, 2026 | 3,000.00 |
| Dec 31, 2025 | 6.65 Mn |
| Dec 31, 2025 | 6.65 Mn |
| Sep 30, 2025 | -170,000.00 |
| Sep 30, 2025 | -170,000.00 |
| Jun 30, 2025 | 684,000.00 |
| Jun 30, 2025 | 684,000.00 |
| Mar 31, 2025 | -818,000.00 |
| Mar 31, 2025 | -818,000.00 |
| Dec 31, 2024 | 2.78 Mn |
| Dec 31, 2024 | 2.78 Mn |
| Sep 30, 2024 | 3.10 Mn |
| Sep 30, 2024 | 3.10 Mn |
| Jun 30, 2024 | 607,000.00 |
| Jun 30, 2024 | 607,000.00 |
| Mar 31, 2024 | 1.07 Mn |
| Mar 31, 2024 | 1.07 Mn |
| Dec 31, 2023 | 68,000.00 |
| Dec 31, 2023 | 68,000.00 |